Cmed Group, which combines clinical research services with a clinical data capture and management system, has strengthened its senior management team with the appointment of Andrew Kellett as chief financial officer (CFO).
Kellett, who was formerly finance director of Genetix Group, a global life sciences diagnostics and digital pathology company, brings on board a wealth of experience in the financial management of international high growth companies in the medical sector.
His appointment strengthens Cmed’s management team as the group accelerates the global expansion of its flagship IT product Timaeus, a next-generation clinical data capture and management solution which is already delivering critical benefits in a number of major international clinical trials.
Kellett spent four years as CFO at Genetix, which was acquired by the Danaher Corporation this year for £63m, and prior to that he was European finance director and global controller for clinical trials and pharmaceutical business development for US-based Quest Diagnostics, a diagnostic lab testing company.
He trained at Coopers and Lybrand and has established a strong track record in financial management, operational leadership in diverse, global companies, as well as extensive experience in driving strategic growth, corporate development activities, mergers and acquisitions.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.